Endothelial Function Impairment in Chronic Venous Insufficiency: Effect of Some Cardiovascular Protectant Agents

Angiology

Volumn 60, Issue 6, 2009, Pages 763-771

  Carrasco, Omar F ^a   Ranero, Alejandra ^b   Hong, Enrique ^c   Vidrio, Horacio ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b HOSPITAL GENERAL DR MANUEL GEA GONZÁLEZ   (Mexico)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

endothelial function; varicose veins; vasoactive drugs

Indexed keywords

CARDIOVASCULAR AGENT;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; COMPARATIVE STUDY; DOPPLER ECHOGRAPHY; DRUG EFFECT; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SAPHENOUS VEIN; VASCULAR ENDOTHELIUM; VASODILATATION; VEIN INSUFFICIENCY;

ADULT; AGED; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SAPHENOUS VEIN; ULTRASONOGRAPHY, DOPPLER, DUPLEX; VASODILATION; VENOUS INSUFFICIENCY;

EID: 77449087706     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319709332108     Document Type: Article

References (43)

1. Bergan JJ, Schmid-Schönbein GW, Smith PD, Nicolaides AN, Boisseau MR, Eklof B. Chronic venous disease. N Engl J Med. 2006;355:488-498.
2. Padberg FT Jr. CEAP classification for chronic venous disease. Dis Mon. 2005;51:176-182.
3. Ibrahim S, MacPherson DR, Goldhaber SZ. Chronic venous insufficiency: mechanisms and management. Am Heart J. 1996;132:856-860.
4. Pascarella L, Schmid-Schönbein GW. Causes of telengiectasias, reticular veins, and varicose veins. Semin Vasc Surg. 2005;18:2-4.
5. Naoum JJ, Hunter GC, Woodside KJ, Chen C. Current advances in the pathogenesis of varicose veins. J Surg Res. 2007;141:311-316.
6. Elsharawy MA, Naim MM, Abdelmaguid EM, Al-Mulhim AA. Role of saphenous vein wall in the pathogenesis of primary varicose veins. Interact CardioVasc Thorac Surg. 2007;6:219-224.
7. Michiels C, Arnould T, Remacle J. Hypoxia-induced activation of endothelial cells as a possible cause of venous diseases: hypothesis. Angiology. 1993;44:639-646.
8. Cines DB, Pollak ES, Buck CA. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91:3527-3561.
9. Michiels C, Arnould T, Remacle J. Endothelial cell responses to hypoxia: initiation of a cascade of cellular interactions. Biochim Biophys Acta. 2000;1497:1-10.
10. Michiels C. Physiological and pathological responses to hypoxia. Am J Pathol. 2004;164:1875-1882.
11. Michiels C, De Leener F, Arnould T. Hypoxia stimulates human endothelial cells to release smooth muscle cell mitogens: role of prostaglandins and bFGF. Exp Cell Res. 1994;213:43-54.
12. Giles TD. Aspects of nitric oxide in health and disease: a focus on hypertension and cardiovascular disease. J Clin Hypertens. 2006;8:2-16.
13. Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N. Basal nitric oxide synthesis in essential hypertension. Lancet. 1997;349:837-842.
14. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol. 2000;130:963-974.
15. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376.
16. Rakici O, Kiziltepe U, Coskun B, Aslamaci S, Akar F. Effects of resveratrol on vascular tone and endothelial function of human saphenous vein and internal mammary artery. Int J Cardiol. 2005;105:209-215.
17. Brunner F, Hoffmann C, Schuller-Petrovic S. Responsiveness of human varicose saphenous veins to vasoactive agents. Br J Clin Pharmacol. 2001;51:219-224.
18. Fu YF, Xiong Y, Fu SH. Captopril restores endotheliumdependent relaxation of rat aortic rings after exposure to homocysteine. J Cardiovasc Pharmacol. 2003;42: 566-572.
19. Prasad A, Tupas-Habib T, Schenke WH, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation. 2000;101:2349-2354.
20. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase byHMGCoA reductase inhibitors. Circulation. 1998;97:1129-1135.
21. Calnek D, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor g ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:52-57.
22. Pittler MH, Ernst E. Horse-chestnut seed extract for chronic venous insufficiency. Arch Dermatol. 1998;134: 1356-1360.
23. Carrasco OF, Vidrio H. Endothelium protectant and contractile effects of the antivaricose principle escin in rat aorta. Vascul Pharmacol. 2007;47:68-73.
24. Gavin KT, Colgan MP, Moore D, Shanik G, Docherty JR. α2c-adrenoceptors mediate contractile responses to noradrenaline in the human saphenous vein. Naunyn Schmiedebergs Arch Pharmacol. 1997;355: 406-411.
25. Thulesius O, Said S, Shuhaiber H, Neglen P, Gjores JE. Endothelial mediated enhancement of noradrenaline induced vascocontstriction in normal and varicose veins. Clin Physiol. 1991;11:153-159.
26. Lowell RC, Gloviczki P, Miller VM. In vitro evaluation of endothelial and smooth muscle function of primary varicose veins. Vasc Surg. 1992;16:679-686.
27. Cracowski JL, Stanke-Labesque F, Sessa C, et al. Functional comparison of the human isolated femoral artery, internalmammary artery, gastroepiploic artery, and saphenous vein. Can J Physiol Pharmacol. 1999;77:770-776.
28. Desai ND, Cohen EA, Taylor D, Fremes SE. Radial Artery Patency Study Investigators. A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. N Engl J Med. 2004;351:2302-2309.
29. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
30. Hollingsworth SJ, Tang CB, Dialynas M, Barker SG. Varicose veins: loss of release of vascular endothelial growth factor and reduced plasma nitric oxide. Eur J Endovasc Surg. 2001;22:551-556.
31. Schuller-Petrovic S, Siedler S, Kern T, Meinhart J, Schmidt K, Brunner F. Imbalance between the endothelial cell-derived contracting factors prostacyclin and angiotensin II and nitric oxide/cyclic GMP in human primary varicosis. Br J Pharmacol. 1997;122:772-778.
32. Chen SX, Song T, Zhou SH, Liu YH, Wu SJ, Liu LY. Protective effects of ACE inhibitors on vascular endothelial dysfunction induced by exogenous advanced oxidation protein products in rats. Eur J Pharmacol. 2008;584:368-375.
33. Bayorh MA, Ganafa AA, Eatman D, Walton M, Feuerstein GZ. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension. Am J Hypertens. 2005;18:1496-1502.
34. Watanabe Y, Sunayama S, Shimada K, et al. Troglitazone improves endothelial dysfunction in patients with insulin resistance. J Atheroscler Thromb. 2000;7:159-163.
35. Nanayakkara PW, van Guldener C, ter Wee PM, et al. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med. 2007;167:1262-1270.
36. Török J, L'upták I, Matúsková J, et al. Comparison of the effect of simvastatin, spironolactone and L-arginine on endothelial function of aorta in hereditary hypertriglyceridemic rats. Physiol Res. 2007;56:S33-S40.
37. Rosenkranz AC, Lob H, Breitenbach T, Berkels R, Roesen R. Endothelial antioxidant actions of dihydropyridines and angiotensin converting enzyme inhibitors. Eur J Pharmacol. 2006;529:55-62.
38. Nakagawa K, Ueno A, Nishikawa Y. Interactions between carnosine and captopril on free radical scavenging activity and angiotensin-converting enzyme activity in vitro. Yakugaku Zasshi. 2006;126:37-42.
39. Horning B, Landmesser U, Kohler C, et al. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation. 2000;103:799-805.
40. Cho DH, Choi YJ, Jo SA, Jo I. Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone. J Biol Chem. 2004;279:2499-2506.
41. Hwang J, Kleinhenz DJ, Lassegue B, Griendling KK, Dikalov S, Hart CM. Peroxisome proliferator-activated receptor-g ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol. 2005;288: C899-C905.
42. Kureishi Y, Luo Z, Shiojima I. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004-1010.
43. Guillaume M, Padioleau F. Veinotonic effect, vascular protection, anti-inflammatory and free radical scavenging properties of horse chestnut extract. Arzneimittelforschung. 1994;44:25-35.